Back to Journals » Biologics: Targets and Therapy » Volume 13 » default
![](https://www.dovepress.com/cr_data/cache/journal_image/8/cope/thumb_100_1000_100.jpg)
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (512)
- Volume 18, 2024 (16)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 13, 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
Chandra A, Kanth R, Thareja S
Biologics: Targets and Therapy 2019, 13:191-200
Published Date: 25 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Rosmarinic acid monotherapy is better than the combination of rosmarinic acid and telmisartan in preventing podocyte detachment and inhibiting the progression of diabetic nephropathy in rats
Samsu N, Soeharto S, Rifai M, Rudijanto A
Biologics: Targets and Therapy 2019, 13:179-190
Published Date: 30 August 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Remicade® (infliximab): 20 years of contributions to science and medicine
Melsheimer R, Geldhof A, Apaolaza I, Schaible T
Biologics: Targets and Therapy 2019, 13:139-178
Published Date: 30 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical utility of ramucirumab in non-small-cell lung cancer
Uprety D
Biologics: Targets and Therapy 2019, 13:133-137
Published Date: 22 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Therapeutic drug monitoring of biologics in psoriasis
Liau MM, Oon HH
Biologics: Targets and Therapy 2019, 13:127-132
Published Date: 5 July 2019
Antitumor and antibacterial properties of virally encoded cationic sequences
Colle JH, Périchon B, Garcia A
Biologics: Targets and Therapy 2019, 13:117-126
Published Date: 25 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab
Lerkvaleekul B, Treepongkaruna S, Ruangwattanapaisarn N, Treesit T, Vilaiyuk S
Biologics: Targets and Therapy 2019, 13:111-116
Published Date: 14 June 2019
TRIP6 functions as a potential oncogene and facilitated proliferation and metastasis of gastric cancer
Zhu L, Xu X, Tang Y, Zhu X
Biologics: Targets and Therapy 2019, 13:101-110
Published Date: 11 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
Salehzadeh F, Mohammadikebar Y, Enteshary A, Ghanbarpour O, Mirzarahimi M
Biologics: Targets and Therapy 2019, 13:97-99
Published Date: 27 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
Caminati M, Bagnasco D, Vaia R, Senna G
Biologics: Targets and Therapy 2019, 13:89-95
Published Date: 22 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau
![](cr_data/cache/submission_images/s199000/199100/fig1_200_200_90.jpg)
Smirnova LM, Vertieva EY, Olisova OY, Anpilogova EM
Biologics: Targets and Therapy 2019, 13:83-87
Published Date: 20 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Dupilumab side effect in a patient with atopic dermatitis: a case report study
![](cr_data/cache/submission_images/s195000/195512/figure-1-_200_200_90.jpeg)
Albader SS, Alharbi AA, Alenezi RF, Alsaif FM
Biologics: Targets and Therapy 2019, 13:79-82
Published Date: 13 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Systematic review of immunomodulatory therapies for hidradenitis suppurativa
Lim SYD, Oon HH
Biologics: Targets and Therapy 2019, 13:53-78
Published Date: 13 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
Cruz E, Kayser V
Biologics: Targets and Therapy 2019, 13:33-51
Published Date: 1 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
Viscido A, Papi C, Latella G, Frieri G
Biologics: Targets and Therapy 2019, 13:23-31
Published Date: 9 April 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, Ravelli A, Knafelz D, Martelossi S, Guariso G, Accomando S, Zuin G, De Giacomo C, Balzani L, Gennari M, Aloi M
Biologics: Targets and Therapy 2019, 13:13-21
Published Date: 3 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
![](cr_data/cache/submission_images/s114000/114530/114530-figure-2_200_200_90.jpg)
Keyel ME, Reynolds CP
Biologics: Targets and Therapy 2019, 13:1-12
Published Date: 21 December 2018